The profile of pleural effusions in oncological patients referred to the cardiothoracic surgery department in a tertiary hospital in Pretoria, South Africa: A retrospective study
Article Sidebar
Main Article Content
Abstract
Background. The presence of a pleural effusion in any oncological patient (patient with known underlying current or previous malignancy) tends to be classified as advanced disease with few curative measures.
Objectives. To establish the aetiology of pleural effusions in oncological patients in our subpopulation. The primary objective was to determine the percentage of proven malignant pleural effusions (MPEs). Secondary objectives were to determine the causes of proven MPEs and proven benign (non-malignant) pleural effusions (non-MPEs), and to determine whether proven non-MPEs change the initial cancer staging of patients.
Methods. This was a retrospective record review of oncological patients admitted with suspected MPE to the Steve Biko Academic Hospital Cardiothoracic Surgery Unit during the period January 2018 - June 2020.
Results. Ninety-one patients met the inclusion criteria. The median (interquartile range) age was 56 (41 - 66) years, and there were 54 females (59.3%) and 37 males (40.7%). Pleural biopsy results confirmed MPE in 80.2% (95% confidence interval 70.6 - 87.8) of cases (n=73/91) and non-MPE in 19.8% (n=18/91). The aetiologies of MPEs in descending order were breast (42.5%), lung (24.7%), genitourinary tract (15.1%), lymphoma (9.6%), other (6.8%) and gastrointestinal tract (1.4%) carcinomas. The aetiologies of the non-MPEs were inflammatory (88.9%) and infective (11.1%) in nature. Among the proven non-MPEs, the results led to a possible cancer downstaging in 6/18 patients (33.3%).
Conclusion. Among oncological patients with pleural effusions referred to our unit, a statistically significant proportion (80.2%) had MPE by pleural tissue confirmation, with breast carcinoma being the most common cause. Of those with proven non-MPE, only a third had a possible cancer downstaging.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication.
How to Cite
References
1. TozzoliR,BassoSMM,D’AurizioF,MetusP,LumachiF.Evaluationofpredictivevalueof pleural CEA in patients with pleural effusions and histological findings. Clin Biochem 2016;49(16-17):1227-1231. https://doi.org/10.1016/j.clinbiochem.2016.08.006
2. Abumossalam AM, Abdelgawad TT, Shebl AM. Malignant pleural effusion: Relationship between thoracoscopic findings and type of malignancy. Egypt J Chest Dis 2015; 64(2):399-404. https://doi.org/10.1016/j.ejcdt.2014.11.026
3. Heffner JE. Management malignant pleural effusions. UpToDate, 2019. https://www- uptodate-com.uplib.idm.oclc.org/contents/management-of-malignant-pleural- effusions (accessed 11 January 2020).
4. Thomas R, Roy B, Maldonado F, Lee YCG. Management of malignant pleural effusions – what is new. Semin Respir Crit Care Med 2019;40(3):323-339. https://doi. org/10.1055/s-0039-1698285
5. Hassan M, Mercer RM, Maskell NA, et al. Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Lung Cancer 2019;137:14-18. https://doi. org/10.1016/j.lungcan.2019.09.003
6. Lumachi F, Mazza F, Ermani M, Chiara GB, Basso SMM. Talc pleurodesis as surgical palliation of patients with malignant pleural effusions: Analysis of factors affecting survival. Anticancer Res 2012;32(11):5071-5074.
7. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl 2):ii32-ii40. https:// doi.org/10.1136/thx.2010.136994
8. KoegelenbergCFN,BennjiSM,BoerE,etal.Thecurrentaetiologyofmalignantpleural effusion in the Western Cape Province, South Africa. S Afr Med J 2018;108(4):275- 277. https://doi.org/10.7196/SAMJ.2017.v108i4.12936
9. Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg 2019;55(1):116-132. https://doi. org/10.1093/ejcts/ezy258
10. Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: Data from the 2012 National Inpatient Sample. Chest 2017;151(4):845-854. https://doi.org/10.1016/j.chest.2016.11.010
11. Kamel MM, Kaffas K. Diagnostic value of ultrasound guided biopsy in patients with malignant pleural effusion. Egypt J Chest Dis 2012;61(4):377-383. https://doi. org/10.1016/j.ejcdt.2012.09.004
12. AllamaAM,Abou-ElelaDH,IbrahimIM.Pleuralandserummarkersfordiagnosisof malignant pleural effusion. Asian Cardiovasc Thorac Ann 2020;28(9):560-565. https:// doi.org/10.1177/0218492320948311
13. Nwafor IA, Nnakenyi EF, Eze JC, Nwidenyi IO. Management of malignant pleural effusion (MPE) in a tertiary hospital in a low-income-country: Challenges and prospects. Ibom Med J 2020;13(3):180-186. https://doi.org/10.61386/imj.v13i3.201
14. Jia J, Marazioti A, Voulgaridis A, et al. Clinical identification of malignant pleural effusions. Transl Oncol 2024;39:101800. https://doi.org/10.1016/j,tranon.2023.101800 15. Thomas R, Roy B, Maldonado F, Lee YCG. Management of malignant pleural effusions: What is new? Semin Respir Crit Care Med 2019;40(3):323-339. https://doi.
org/10.1055/s-0039-1698285
16. Mitchell MA, Deschner E, Dhaliwal I, et al. Patient perspectives on the use of indwelling pleural catheters in malignant pleural effusions. Thorax 2023;78(11):1111- 1117. https://doi.org/10.1136/thorax-2022-219449
17. Kim CH, Oh HG, Lee SY, et al. Differential diagnosis between lymphoma-associated malignant pleural effusion and tuberculous pleural effusion. Ann Transl Med 2019;7(16):373. https://doi.org/10.21037/atm.2019.07.17
18. Dixit R, Agarwal KC, Gokhroo A, et al. Diagnosis and management options in malignant pleural effusions. Lung India 2017;34(2):160-166. https://doi. org/10.4103/0970-2113.201305
19. Bashour SI, Mankidy BJ, Lazarus DR. Update on the diagnosis and management of malignant pleural effusions. Respir Med 2022;196:106802. https://doi.org/10.1016/j. rmed.2022.106802
20. Dipper A, Bhatnagar R, Maskell N. Management of malignant pleural effusions. Curr Opin Pulm Med 2020;26(4):341-345. https://doi.org/10.1097/MCP.0000000000000685 21. Kapp CM, Lee HJ. Malignant pleural effusions. Clin Chest Med 2021;42(4):687-696.
https://doi.org/10.1016/j.ccm.2021.08.004
22. Hughes SM, Carmichael JJ. Malignant pleural effusion: Updates in diagnosis and management. Life (Basel) 2023;13(1):115. https://doi.org/10.3390/life13010115
23. Shaw JA, Irusen EM. The perplexing pleura: Diagnosing tuberculous pleural effusions in the era of drug resistance. Afr J Thorac Crit Care Med 2019;25(2):35-36. https://doi. org/10.7196/AJTC-CM.2019.v25i2.020
24. Shaw JA, Louw EA, Koegelenberg CFN. A practical approach to the diagnosis and management of malignant pleural effusions in resource-constrained settings. Breathe (Sheff) 2023;19(4):230140. https://doi.org/10.1183/20734735.0140-2023
25. Fitzgerald DB, Koegelenberg CFN, Yasufuku K, Lee YCG. Surgical and non-surgical management of malignant pleural effusions. Expert Rev Respir Med 2018;12(1):15-26. https://doi.org/10.1080/17476348.2018.1398085